Related Research Of Isoglycyrrhizinate Magnesium Prevent Radiation Induced Liver Injury

Background:Gastric carcinoma, pancreatic carcinoma and gallbladder carcinoma are the most common digestive system cancer tumors. The treatment of abdominal malignant tumors is a comprehensive treatment based on surgery. Patients often have no obvious clinical symptoms or clinical manifestations, and it is difficult to find and treatment. Therefore, the clinical treatment in patients with advanced. Although locally advanced patients can be operated on.Treatment failure due to local recurrence and regional lymph node metastasis often results in failure. The curative effect of chemotherapy on patients with advanced malignant tumor of upper abdomen is not satisfactory.The main treatment of radiotherapy and chemotherapy is to reduce the local recurrence and distant metastasis. With the maturity of three dimensional conformal radiation therapy, the local control rate of tumor and the survival rate of the patients were significantly improved. The incidence of side effects and treatment related mortality is relatively low. Therefore, radiotherapy and chemotherapy have become the main treatment of the middle and late stage of abdominal malignant tumors. Radiation ray not only direct exposure of the tumor target region and the adjacent organs also produced a dose of radiation, especially the liver. Because the liver tissue of ray hypersensitivity of the perceptual, the liver is more likely to occur radiation damage. This not only limits the dose of radiation therapy on the epigastrium, but also the impact of the radiation therapy and efficacy of radiotherapy process.Magnesium Isoglycyrrhizinate is major drug for prevention and treatment of liver injury in the present for research. It is extracted from Chinese herbal medicine with a high purity of 18α-isomer glycyrrhizic acid. A number of clinical trials showed that magnesium can prevent and treat drug induced liver injury. The mechanism is related to anti-inflammation, protecting liver cell membrane, scavenging oxygen free radicals and promoting the regeneration of liver cells, and the function of repairing, removing toxin and improving liver function. Magnesium is widely used in the drug induced liver injury caused by anti-tumor drugs and anti-tuberculosis drugs. Animal studies have shown that magnesium can prevent the occurrence of liver injury. The mechanism is related to scavenging oxygen free radicals, anti cell oxidation, inhibiting the degeneration and necrosis of liver cells and fibrosis, inhibiting the inflammatory reaction. It can reduce the degree of ALT, AST and TBIL increased. However, the clinical trials of Magnesium in the prevention of radiation induced liver injury are still rare. Objective:By radiological monitoring before and after treatment, the differences in the changes of liver function and the patient’s clinical manifestations, to explore different glycyrrhizic acid magnesium whether of radiation-induced liver injury with preventive effect. Methods:Collection of 60 patients with epigastrium radiation therapy in Affiliated Hospital of Yan’an University from January 2014 to December 2015. Patients receiving radiotherapy were randomly assigned to the trial group and the control group. 3D-CRT was used in the 2 groups. Intravenous infusion of magnesium 200 mg in the treatment group was dissolved in 9% Sodium Chloride Injection 250 m L. One times a day for 4 weeks. The control group was the blank control, do not use any hepatoprotectants. Check before and weeks radiotherapy in the treatment of liver function. SPSS 19 statistical software was used to analyze the AST, ALT and TBIL of the patients, and to determine whether magnesium can prevent the liver injury induced by radiation. Measurement data were expressed as mean x ±s, and the t-test was used to test. Counting data using x2-test and Fisher exact test. Statistical analysis of volume percentage using non-parametric rank sum test. All hypothesis tests were two-sided test, the test level was α=0.05. When P<0.05, the differences were statistically significant. Outcomes:1.There was no significant difference(P>0.05) in gender, age, height, weight, tumor type and clinical stage between the two groups.2.There was no significant difference(P>0.05) in the liver volume of V20 and V30 between the two groups.3.Two groups of patients before radiotherapy and weekly liver function indexes of ALT, AST and TBIL showed an increasing trend.4.Radiotherapy of magnesium isoglycyrrhizinate combined with radiotherapy group and radiotherapy group liver function level there were no significant statistical differences(P>0.05).5.The two groups of ALT, AST and TBIL were higher than those before radiotherapy. There was no significant difference(P>0.05) before and after radiotherapy in the combination of magnesium and magnesium. There were significant differences(P<0.05) in the comparison of the radiotherapy group before and after radiotherapy.6.The degree of ALT, AST and TBIL value of magnesium combined radiotherapy group after radiotherapy was lower than that of the simple radiotherapy group, and there was significant difference(P<0.05) between the two groups.7.Adverse reactions: The two groups of patients in the treatment of different degrees of liver dysfunction, the treatment group was significantly lower than the control group. Two groups of patients did not appear III- IV gastrointestinal reaction and bone marrow suppression and other serious adverse reactions. The adverse reactions of magnesium in the treatment group were not related to magnesium. Conclusions:1.Magnesium can decrease the level of ALT, AST and TBIL in serum.2.Magnesium may have a preventive effect on radiation induced liver injury.